BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shuker N, van Gelder T, Hesselink DA. Intra-patient variability in tacrolimus exposure: causes, consequences for clinical management. Transplant Rev (Orlando). 2015;29:78-84. [PMID: 25687818 DOI: 10.1016/j.trre.2015.01.002] [Cited by in Crossref: 104] [Cited by in F6Publishing: 92] [Article Influence: 14.9] [Reference Citation Analysis]
Number Citing Articles
1 Yabuki H, Matsuda Y, Watanabe T, Eba S, Hoshi F, Hirama T, Oishi H, Sado T, Noda M, Sakurada A, Kikuchi M, Yamaguchi H, Mano N, Okada Y. Plasma mycophenolic acid concentration and the clinical outcome after lung transplantation. Clin Transplant 2020;34. [DOI: 10.1111/ctr.14088] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Alabdulkarim Z, Al‐jedai A, Alkortas D, Alhasan K, Devol E. Efficacy and safety of three times daily dosing of tacrolimus in pediatric kidney transplantation patients: A single‐center comparative study. Pediatr Transplant 2020;24. [DOI: 10.1111/petr.13733] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Ko H, Kim HK, Chung C, Han A, Min SK, Ha J, Min S. Association between medication adherence and intrapatient variability in tacrolimus concentration among stable kidney transplant recipients. Sci Rep 2021;11:5397. [PMID: 33686160 DOI: 10.1038/s41598-021-84868-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Jouve T, Rostaing L, Malvezzi P. New formulations of tacrolimus and prevention of acute and chronic rejections in adult kidney-transplant recipients. Expert Opinion on Drug Safety 2017;16:845-55. [DOI: 10.1080/14740338.2017.1328051] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
5 Bunthof KLW, Al-Hassany L, Nakshbandi G, Hesselink DA, van Schaik RHN, Ten Dam MAGJ, Baas MC, Hilbrands LB, van Gelder T. A randomized crossover study comparing different tacrolimus formulations to reduce intrapatient variability in tacrolimus exposure in kidney transplant recipients. Clin Transl Sci 2021. [PMID: 34905302 DOI: 10.1111/cts.13206] [Reference Citation Analysis]
6 Cherukuri A, Salama AD, Mehta R, Mohib K, Zheng L, Magee C, Harber M, Stauss H, Baker RJ, Tevar A, Landsittel D, Lakkis FG, Hariharan S, Rothstein DM. Transitional B cell cytokines predict renal allograft outcomes. Sci Transl Med 2021;13:eabe4929. [PMID: 33627487 DOI: 10.1126/scitranslmed.abe4929] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
7 Barrail-Tran A, Goldwirt L, Gelé T, Laforest C, Lavenu A, Danjou H, Radenne S, Leroy V, Houssel-Debry P, Duvoux C, Kamar N, De Ledinghen V, Canva V, Conti F, Durand F, D'Alteroche L, Botta-Fridlund D, Moreno C, Cagnot C, Samuel D, Fougerou-Leurent C, Pageaux GP, Duclos-Vallée JC, Taburet AM, Coilly A. Comparison of the effect of direct-acting antiviral with and without ribavirin on cyclosporine and tacrolimus clearance values: results from the ANRS CO23 CUPILT cohort. Eur J Clin Pharmacol 2019;75:1555-63. [PMID: 31384986 DOI: 10.1007/s00228-019-02725-x] [Reference Citation Analysis]
8 Sirota M, Heyrend C, Ou Z, Masotti S, Griffiths E, Molina K. Impact of tacrolimus variability on pediatric heart transplant outcomes. Pediatr Transplant 2021;:e14043. [PMID: 34390091 DOI: 10.1111/petr.14043] [Reference Citation Analysis]
9 Seibert SR, Schladt DP, Wu B, Guan W, Dorr C, Remmel RP, Matas AJ, Mannon RB, Israni AK, Oetting WS, Jacobson PA. Tacrolimus trough and dose intra-patient variability and CYP3A5 genotype: Effects on acute rejection and graft failure in European American and African American kidney transplant recipients. Clin Transplant 2018;32:e13424. [PMID: 30318646 DOI: 10.1111/ctr.13424] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
10 Chamoun B, Torres IB, Gabaldón A, Sellarés J, Perelló M, Castellá E, Guri X, Salcedo M, Toapanta NG, Cidraque I, Moreso F, Seron D. Progression of Interstitial Fibrosis and Tubular Atrophy in Low Immunological Risk Renal Transplants Monitored by Sequential Surveillance Biopsies: The Influence of TAC Exposure and Metabolism. J Clin Med 2021;10:E141. [PMID: 33406589 DOI: 10.3390/jcm10010141] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Larpparisuth N, Skulratanasak P, Vongwiwatana A, Premasathian N. Effect on Dosage Change and Intrapatient Variability After Conversion From Twice-Daily to Once-Daily Tacrolimus Among Thai Kidney Transplant Patients With and Without CYP3A4/5 Inhibitors. Transplant Proc 2019;51:2620-3. [PMID: 31474450 DOI: 10.1016/j.transproceed.2019.02.065] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
12 Shen CL, Yang AH, Lien TJ, Tarng DC, Yang CY. Tacrolimus Blood Level Fluctuation Predisposes to Coexisting BK Virus Nephropathy and Acute Allograft Rejection. Sci Rep 2017;7:1986. [PMID: 28512328 DOI: 10.1038/s41598-017-02140-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.6] [Reference Citation Analysis]
13 Brooks E, Tett SE, Isbel NM, Staatz CE. Population Pharmacokinetic Modelling and Bayesian Estimation of Tacrolimus Exposure: Is this Clinically Useful for Dosage Prediction Yet? Clin Pharmacokinet 2016;55:1295-335. [DOI: 10.1007/s40262-016-0396-1] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 7.8] [Reference Citation Analysis]
14 Moadel D, Chism K. Medical Marijuana-Induced Tacrolimus Toxicity. Psychosomatics 2019;60:603-5. [DOI: 10.1016/j.psym.2019.01.009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
15 Cheung CY, Chan KM, Wong YT, Chak WL, Bekers O, van Hooff JP. Impact of CYP3A5 Genetic Polymorphism on Intrapatient Variability of Tacrolimus Exposure in Chinese Kidney Transplant Recipients. Transplantation Proceedings 2019;51:1754-7. [DOI: 10.1016/j.transproceed.2019.04.019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
16 Riva N, Schaiquevich P, Cáceres Guido P, Halac E, Dip M, Imventarza O. Pharmacoepidemiology of tacrolimus in pediatric liver transplantation. Pediatr Transplantation 2017;21:e12982. [DOI: 10.1111/petr.12982] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
17 van der Veer MAA, Nangrahary N, Hesselink DA, Erler NS, Metselaar HJ, van Gelder T, Darwish Murad S. High Intrapatient Variability in Tacrolimus Exposure Is Not Associated With Immune-mediated Graft Injury After Liver Transplantation. Transplantation 2019;103:2329-37. [PMID: 30801539 DOI: 10.1097/TP.0000000000002680] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 3.5] [Reference Citation Analysis]
18 Han Y, Zhou H, Cai J, Huang J, Zhang J, Shi S, Liu Y, Zhang Y. Prediction of tacrolimus dosage in the early period after heart transplantation: a population pharmacokinetic approach. Pharmacogenomics 2019;20:21-35. [DOI: 10.2217/pgs-2018-0116] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
19 Zwart TC, Gokoel SRM, van der Boog PJM, de Fijter JW, Kweekel DM, Swen JJ, Guchelaar HJ, Moes DJAR. Therapeutic drug monitoring of tacrolimus and mycophenolic acid in outpatient renal transplant recipients using a volumetric dried blood spot sampling device. Br J Clin Pharmacol 2018;84:2889-902. [PMID: 30176064 DOI: 10.1111/bcp.13755] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 8.3] [Reference Citation Analysis]
20 Francke MI, de Winter BC, Elens L, Lloberas N, Hesselink DA. The pharmacogenetics of tacrolimus and its implications for personalized therapy in kidney transplant recipients. Expert Review of Precision Medicine and Drug Development 2020;5:313-6. [DOI: 10.1080/23808993.2020.1776107] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Brazeau DA, Attwood K, Meaney CJ, Wilding GE, Consiglio JD, Chang SS, Gundroo A, Venuto RC, Cooper L, Tornatore KM. Beyond Single Nucleotide Polymorphisms: CYP3A5367 Composite and ABCB1 Haplotype Associations to Tacrolimus Pharmacokinetics in Black and White Renal Transplant Recipients. Front Genet 2020;11:889. [PMID: 32849848 DOI: 10.3389/fgene.2020.00889] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Hwang S, Song GW, Jung DH, Park GC, Ahn CS, Moon DB, Ha TY, Kim KH, Lee SG. Intra-individual variability of mycophenolic acid concentration according to renal function in liver transplant recipients receiving mycophenolate monotherapy. Ann Hepatobiliary Pancreat Surg 2017;21:11-6. [PMID: 28317040 DOI: 10.14701/ahbps.2017.21.1.11] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
23 Kuypers DRJ. From Nonadherence to Adherence. Transplantation 2020;104:1330-40. [PMID: 31929426 DOI: 10.1097/TP.0000000000003112] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
24 Kannegieter NM, Hesselink DA, Dieterich M, de Graav GN, Kraaijeveld R, Baan CC. Analysis of NFATc1 amplification in T cells for pharmacodynamic monitoring of tacrolimus in kidney transplant recipients. PLoS One 2018;13:e0201113. [PMID: 30036394 DOI: 10.1371/journal.pone.0201113] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
25 Wang R, Wang W, Ma K, Duan X, Wang F, Huang M, Zhang W, Liang T. Variation in Tacrolimus Trough Concentrations in Liver Transplant Patients Undergoing Endoscopic Retrograde Cholangiopancreatography: A Retrospective, Observational Study. Front Pharmacol 2020;11:1252. [PMID: 32973503 DOI: 10.3389/fphar.2020.01252] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Jung HY, Seong SJ, Choi JY, Cho JH, Park SH, Kim CD, Yoon YR, Kim HK, Huh S, Yoon SH, Lee JS, Kim YL. The efficacy and stability of an information and communication technology-based centralized monitoring system of adherence to immunosuppressive medication in kidney transplant recipients: study protocol for a randomized controlled trial. Trials 2017;18:480. [PMID: 29037222 DOI: 10.1186/s13063-017-2221-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
27 Schumacher L, Leino AD, Park JM. Tacrolimus intrapatient variability in solid organ transplantation: A multiorgan perspective. Pharmacotherapy 2021;41:103-18. [PMID: 33131078 DOI: 10.1002/phar.2480] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
28 van Gelder T, Meziyerh S, Swen JJ, de Vries APJ, Moes DJAR. The Clinical Impact of the C0/D Ratio and the CYP3A5 Genotype on Outcome in Tacrolimus Treated Kidney Transplant Recipients. Front Pharmacol 2020;11:1142. [PMID: 32848756 DOI: 10.3389/fphar.2020.01142] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
29 Yin S, Huang Z, Wang Z, Fan Y, Wang X, Song T, Lin T. Early Monitoring and Subsequent Gain of Tacrolimus Time-In-Therapeutic Range May Improve Clinical Outcomes After Living Kidney Transplantation. Ther Drug Monit 2021;43:728-35. [PMID: 34780391 DOI: 10.1097/FTD.0000000000000881] [Reference Citation Analysis]
30 Stefanović NZ, Veličković-Radovanović RM, Danković KS, Mitić BP, Paunović GJ, Cvetković MB, Cvetković TP. Combined Effect of Inter- and Intrapatient Variability in Tacrolimus Exposure on Graft Impairment Within a 3-Year Period Following Kidney Transplantation: A Single-Center Experience. Eur J Drug Metab Pharmacokinet 2020;45:749-60. [PMID: 32886348 DOI: 10.1007/s13318-020-00644-2] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
31 Udomkarnjananun S, Francke MI, De Winter BCM, Mulder MB, Baan CC, Metselaar HJ, den Hoed CM, Hesselink DA. Therapeutic drug monitoring of immunosuppressive drugs in hepatology and gastroenterology. Best Pract Res Clin Gastroenterol 2021;54-55:101756. [PMID: 34874840 DOI: 10.1016/j.bpg.2021.101756] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Riva N, Dip M, Halac E, Cáceres Guido P, Woillard JB, Licciardone N, Chan D, Buendía J, Borgnia D, Bosaleh A, de Davila MT, Imventarza O, Schaiquevich P. Survival Time to Biopsy-Proven Acute Rejection and Tacrolimus Adverse Drug Reactions in Pediatric Liver Transplantation. Ther Drug Monit 2018;40:401-10. [PMID: 29621122 DOI: 10.1097/FTD.0000000000000517] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 1.8] [Reference Citation Analysis]
33 Gokoel SRM, Zwart TC, Moes DJAR, van der Boog PJM, de Fijter JW. No Apparent Influence of Nonadherence on Tacrolimus Intrapatient Variability in Stable Kidney Transplant Recipients. Ther Drug Monit 2020;42:702-9. [PMID: 32941396 DOI: 10.1097/FTD.0000000000000772] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
34 Brooks E, Tett SE, Isbel NM, McWhinney B, Staatz CE. Evaluation of Bayesian Forecasting Methods for Prediction of Tacrolimus Exposure Using Samples Taken on Two Occasions in Adult Kidney Transplant Recipients. Ther Drug Monit 2021;43:238-46. [PMID: 32932413 DOI: 10.1097/FTD.0000000000000814] [Reference Citation Analysis]
35 Fischman C, Fribourg M, Fabrizio G, Cioni M, Comoli P, Nocera A, Cardillo M, Cantarelli C, Gallon L, Petrosyan A, Da Sacco S, Perin L, Cravedi P. Circulating B Cells With Memory and Antibody-Secreting Phenotypes Are Detectable in Pediatric Kidney Transplant Recipients Before the Development of Antibody-Mediated Rejection. Transplant Direct 2019;5:e481. [PMID: 31579809 DOI: 10.1097/TXD.0000000000000914] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
36 Krause AV, Bertram A, Nöhre M, Bauer-Hohmann M, Schiffer M, de Zwaan M. Use of an electronic medication monitoring device to estimate medication adherence in kidney transplant patients. Transl Behav Med 2021;11:842-51. [PMID: 33710349 DOI: 10.1093/tbm/ibaa122] [Reference Citation Analysis]
37 Vanhove T, Vermeulen T, Annaert P, Lerut E, Kuypers DRJ. High Intrapatient Variability of Tacrolimus Concentrations Predicts Accelerated Progression of Chronic Histologic Lesions in Renal Recipients. Am J Transplant. 2016;16:2954-2963. [PMID: 27013142 DOI: 10.1111/ajt.13803] [Cited by in Crossref: 70] [Cited by in F6Publishing: 63] [Article Influence: 11.7] [Reference Citation Analysis]
38 Egeland EJ, Robertsen I, Hermann M, Midtvedt K, Størset E, Gustavsen MT, Reisæter AV, Klaasen R, Bergan S, Holdaas H, Hartmann A, Åsberg A. High Tacrolimus Clearance Is a Risk Factor for Acute Rejection in the Early Phase After Renal Transplantation. Transplantation 2017;101:e273-9. [DOI: 10.1097/tp.0000000000001796] [Cited by in Crossref: 28] [Cited by in F6Publishing: 12] [Article Influence: 5.6] [Reference Citation Analysis]
39 Guo Y, Crnkovic CM, Won KJ, Yang X, Lee JR, Orjala J, Lee H, Jeong H. Commensal Gut Bacteria Convert the Immunosuppressant Tacrolimus to Less Potent Metabolites. Drug Metab Dispos. 2019;47:194-202. [PMID: 30598508 DOI: 10.1124/dmd.118.084772] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 7.3] [Reference Citation Analysis]
40 Vadcharavivad S, Saengram W, Phupradit A, Poolsup N, Chancharoenthana W. Once-Daily versus Twice-Daily Tacrolimus in Kidney Transplantation: A Systematic Review and Meta-analysis of Observational Studies. Drugs 2019;79:1947-62. [PMID: 31713065 DOI: 10.1007/s40265-019-01217-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
41 Kaya Aksoy G, Comak E, Koyun M, Akbaş H, Akkaya B, Aydınlı B, Uçar F, Akman S. Tacrolimus Variability: A Cause of Donor-Specific Anti-HLA Antibody Formation in Children. Eur J Drug Metab Pharmacokinet 2019;44:539-48. [DOI: 10.1007/s13318-019-00544-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
42 Kim JH, Han N, Kim MG, Yun HY, Lee S, Bae E, Kim YS, Kim IW, Oh JM. Increased Exposure of Tacrolimus by Co-administered Mycophenolate Mofetil: Population Pharmacokinetic Analysis in Healthy Volunteers. Sci Rep 2018;8:1687. [PMID: 29374217 DOI: 10.1038/s41598-018-20071-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
43 Herblum J, Dacouris N, Huang M, Zaltzman J, Prasad GVR, Nash M, Chen L. Retrospective Analysis of Tacrolimus Intrapatient Variability as a Measure of Medication Adherence. Can J Kidney Health Dis 2021;8:20543581211021742. [PMID: 34188946 DOI: 10.1177/20543581211021742] [Reference Citation Analysis]
44 Gonzales HM, McGillicuddy JW, Rohan V, Chandler JL, Nadig SN, Dubay DA, Taber DJ. A comprehensive review of the impact of tacrolimus intrapatient variability on clinical outcomes in kidney transplantation. Am J Transplant 2020;20:1969-83. [PMID: 32406604 DOI: 10.1111/ajt.16002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
45 Baghai Arassi M, Zeller G, Karcher N, Zimmermann M, Toenshoff B. The gut microbiome in solid organ transplantation. Pediatr Transplant 2020;24:e13866. [PMID: 32997434 DOI: 10.1111/petr.13866] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
46 Brunet M, van Gelder T, Åsberg A, Haufroid V, Hesselink DA, Langman L, Lemaitre F, Marquet P, Seger C, Shipkova M, Vinks A, Wallemacq P, Wieland E, Woillard JB, Barten MJ, Budde K, Colom H, Dieterlen M, Elens L, Johnson-davis KL, Kunicki PK, Macphee I, Masuda S, Mathew BS, Millán O, Mizuno T, Moes DAR, Monchaud C, Noceti O, Pawinski T, Picard N, van Schaik R, Sommerer C, Vethe NT, de Winter B, Christians U, Bergan S. Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report. Therapeutic Drug Monitoring 2019;41:261-307. [DOI: 10.1097/ftd.0000000000000640] [Cited by in Crossref: 131] [Cited by in F6Publishing: 46] [Article Influence: 43.7] [Reference Citation Analysis]
47 Dorr CR, Oetting WS, Jacobson PA, Israni AK. Genetics of acute rejection after kidney transplantation. Transpl Int 2018;31:263-77. [PMID: 29030886 DOI: 10.1111/tri.13084] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
48 Taber DJ, Su Z, Fleming JN, Pilch NA, Morinelli T, Mauldin P, Dubay D. The impact of time-varying clinical surrogates on disparities in African-American kidney transplant recipients - a retrospective longitudinal cohort study. Transpl Int 2019;32:84-94. [PMID: 30176087 DOI: 10.1111/tri.13338] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
49 Stifft F, Undre N, van Hooff JP, Christiaans MHL. Effect of Breakfast on the Exposure of the Once-Daily Tacrolimus Formulation in Stable Kidney Transplant Recipients. Therapeutic Drug Monitoring 2016;38:456-62. [DOI: 10.1097/ftd.0000000000000311] [Cited by in Crossref: 7] [Article Influence: 1.2] [Reference Citation Analysis]
50 Prytuła A, van Gelder T. Clinical aspects of tacrolimus use in paediatric renal transplant recipients. Pediatr Nephrol 2019;34:31-43. [DOI: 10.1007/s00467-018-3892-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
51 Defrancq C, De Wilde N, Raes A, Van Biervliet S, Vande Velde S, Van Winckel M, De Bruyne R, Prytuła A. Intra‐patient variability in tacrolimus exposure in pediatric liver transplant recipients: Evolution, risk factors, and impact on patient outcomes. Pediatr Transplant 2019;23. [DOI: 10.1111/petr.13388] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
52 Okabe M, Morishita T, Ichiki T, Kawaguchi Y, Lee Y, Ohbiki M, Goto M, Osaki M, Araie H, Goto T, Ozawa Y, Miyamura K. The stability of initial tacrolimus concentration following allogeneic hematopoietic stem cell transplantation reduces the risk of acute GVHD. Clin Transplant 2020;34:e14052. [PMID: 33427361 DOI: 10.1111/ctr.14052] [Reference Citation Analysis]
53 Stelzer D, Weber A, Ihle F, Matthes S, Ceelen F, Zimmermann G, Kneidinger N, Schramm R, Winter H, Zoller M, Vogeser M, Behr J, Neurohr C. Comparing Azole Plasma Trough Levels in Lung Transplant Recipients: Percentage of Therapeutic Levels and Intrapatient Variability. Ther Drug Monit 2017;39:93-101. [PMID: 28282366 DOI: 10.1097/FTD.0000000000000371] [Cited by in Crossref: 21] [Cited by in F6Publishing: 5] [Article Influence: 4.2] [Reference Citation Analysis]
54 Sablik KA, Clahsen-van Groningen MC, Hesselink DA, van Gelder T, Betjes MGH. Tacrolimus intra-patient variability is not associated with chronic active antibody mediated rejection. PLoS One 2018;13:e0196552. [PMID: 29746495 DOI: 10.1371/journal.pone.0196552] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 4.8] [Reference Citation Analysis]
55 Rodrigo E, Segundo DS, Fernández-Fresnedo G, López-Hoyos M, Benito A, Ruiz JC, de Cos MA, Arias M. Within-Patient Variability in Tacrolimus Blood Levels Predicts Kidney Graft Loss and Donor-Specific Antibody Development. Transplantation 2016;100:2479-85. [PMID: 26703349 DOI: 10.1097/TP.0000000000001040] [Cited by in Crossref: 113] [Cited by in F6Publishing: 46] [Article Influence: 22.6] [Reference Citation Analysis]
56 Tan T, Bunnapradist S. Comparing the pharmacokinetics of extended-release tacrolimus (LCP-TAC) to immediate-release formulations in kidney transplant patients. Expert Opin Drug Metab Toxicol 2021;17:1175-86. [PMID: 34459696 DOI: 10.1080/17425255.2021.1974399] [Reference Citation Analysis]
57 Arias M, Serón D, Herrero I, Rush DN, Wiebe C, Nickerson PW, Ussetti P, Rodrigo E, de Cos M. Subclinical Antibody-Mediated Rejection. Transplantation 2017;101:S1-S18. [DOI: 10.1097/tp.0000000000001735] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
58 Kuypers DRJ. Intrapatient Variability of Tacrolimus Exposure in Solid Organ Transplantation: A Novel Marker for Clinical Outcome. Clin Pharmacol Ther 2020;107:347-58. [PMID: 31449663 DOI: 10.1002/cpt.1618] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 10.3] [Reference Citation Analysis]
59 Parodi E, La Porta E, Russo R, Marsano L, Bellino D, Paoletti E, Massarino F, Sofia A, Garibotto G, Esposito P, Murugavel A, Cappadona F, Fontana I, Viazzi F, Picciotto D. Ten-Year Efficacy and Safety of Once-Daily Tacrolimus in Kidney Transplant: A Prospective Cohort Study. Transplantation Proceedings 2020;52:3112-7. [DOI: 10.1016/j.transproceed.2020.02.149] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
60 McGillicuddy J, Chandler J, Sox L, Mueller M, Nemeth L, Baliga P, Treiber F. "Smartphone Medication Adherence Saves Kidneys" for Kidney Transplantation Recipients: Protocol for a Randomized Controlled Trial. JMIR Res Protoc 2019;8:e13351. [PMID: 31228175 DOI: 10.2196/13351] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
61 Grinyó JM. Renal allograft performance in immigrant transplant recipients. Transpl Int 2020;33:1387-9. [PMID: 32668492 DOI: 10.1111/tri.13702] [Reference Citation Analysis]
62 Cherukuri A, Mehta R, Sharma A, Sood P, Zeevi A, Tevar AD, Rothstein DM, Hariharan S. Post-transplant donor specific antibody is associated with poor kidney transplant outcomes only when combined with both T-cell-mediated rejection and non-adherence. Kidney Int 2019;96:202-13. [PMID: 31029504 DOI: 10.1016/j.kint.2019.01.033] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
63 Anger LB, Doligalski CT. Solid organ transplant pharmacotherapy: Complicated and continually changing. Pharmacotherapy 2021;41:4-5. [PMID: 33598986 DOI: 10.1002/phar.2492] [Reference Citation Analysis]
64 Thongprayoon C, Hansrivijit P, Kovvuru K, Kanduri SR, Bathini T, Pivovarova A, Smith JR, Cheungpasitporn W. Impacts of High Intra- and Inter-Individual Variability in Tacrolimus Pharmacokinetics and Fast Tacrolimus Metabolism on Outcomes of Solid Organ Transplant Recipients. J Clin Med 2020;9:E2193. [PMID: 32664531 DOI: 10.3390/jcm9072193] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
65 Leino AD, Pai MP. Maintenance Immunosuppression in Solid Organ Transplantation: Integrating Novel Pharmacodynamic Biomarkers to Inform Calcineurin Inhibitor Dose Selection. Clin Pharmacokinet 2020;59:1317-34. [PMID: 32720300 DOI: 10.1007/s40262-020-00923-w] [Reference Citation Analysis]
66 Cai X, Li R, Sheng C, Tao Y, Zhang Q, Zhang X, Li J, Shen C, Qiu X, Wang Z, Jiao Z. Systematic external evaluation of published population pharmacokinetic models for tacrolimus in adult liver transplant recipients. European Journal of Pharmaceutical Sciences 2020;145:105237. [DOI: 10.1016/j.ejps.2020.105237] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
67 Süsal C, Döhler B. Late intra‐patient tacrolimus trough level variability as a major problem in kidney transplantation: A Collaborative Transplant Study Report. Am J Transplant 2019;19:2805-13. [DOI: 10.1111/ajt.15346] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
68 Girerd S, Schikowski J, Girerd N, Duarte K, Busby H, Gambier N, Ladrière M, Kessler M, Frimat L, Aarnink A. Impact of reduced exposure to calcineurin inhibitors on the development of de novo DSA: a cohort of non-immunized first kidney graft recipients between 2007 and 2014. BMC Nephrol 2018;19:232. [PMID: 30219043 DOI: 10.1186/s12882-018-1014-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
69 Leino AD, Emoto C, Fukuda T, Privitera M, Vinks AA, Alloway RR. Evidence of a clinically significant drug-drug interaction between cannabidiol and tacrolimus. Am J Transplant 2019;19:2944-8. [PMID: 31012522 DOI: 10.1111/ajt.15398] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 9.3] [Reference Citation Analysis]
70 Goldsmith PM, Bottomley MJ, Okechukwu O, Ross VC, Ghita R, Wandless D, Falconer SJ, Papachristos S, Nash P, Androshchuk V, Clancy M; Transplant Audit Collaborative. Impact of intrapatient variability (IPV) in tacrolimus trough levels on long-term renal transplant function: multicentre collaborative retrospective cohort study protocol. BMJ Open 2017;7:e016144. [PMID: 28756385 DOI: 10.1136/bmjopen-2017-016144] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
71 Ro H, Jeong JC, Kong JM, Min JW, Park SK, Lee J, Koo TY, Yang J, Kim MS, Hwang S, Ahn C. The tacrolimus metabolism affect post‐transplant outcome mediating acute rejection and delayed graft function: analysis from Korean Organ Transplantation Registry data. Transpl Int 2021;34:163-74. [DOI: 10.1111/tri.13777] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
72 Groll AH, Townsend R, Desai A, Azie N, Jones M, Engelhardt M, Schmitt-Hoffman AH, Brüggemann RJM. Drug-drug interactions between triazole antifungal agents used to treat invasive aspergillosis and immunosuppressants metabolized by cytochrome P450 3A4. Transpl Infect Dis 2017;19. [PMID: 28722255 DOI: 10.1111/tid.12751] [Cited by in Crossref: 45] [Cited by in F6Publishing: 42] [Article Influence: 9.0] [Reference Citation Analysis]
73 Del Bello A, Congy-Jolivet N, Danjoux M, Muscari F, Lavayssière L, Esposito L, Hebral AL, Bellière J, Kamar N. High tacrolimus intra-patient variability is associated with graft rejection, and de novo donor-specific antibodies occurrence after liver transplantation. World J Gastroenterol 2018; 24(16): 1795-1802 [PMID: 29713132 DOI: 10.3748/wjg.v24.i16.1795] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 27] [Article Influence: 9.3] [Reference Citation Analysis]
74 Crespo M, Zárraga S, Alonso Á, Beneyto I, Díaz Corte C, Fernandez Rodriguez AM, Franco A, Hernández D, González-roncero FM, Jiménez Martín C, Jimeno L, Lauzurica Valdemoros L, Llorente S, Mazuecos A, Osuna A, Ramos JP, Rodríguez Benot A, Ruiz San Millán JC, Sánchez Fructuoso A, Torregrosa J, Guirado L. Monitoring of Donor-specific Anti-HLA Antibodies and Management of Immunosuppression in Kidney Transplant Recipients: An Evidence-based Expert Paper. Transplantation 2020;104:S1-S12. [DOI: 10.1097/tp.0000000000003270] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
75 Abu Bakar K, Mohamad NA, Hodi Z, McCulloch T, Williams A, Christian M, Key T, Kim JJ. Defining a threshold for tacrolimus intra-patient variability associated with late acute cellular rejection in paediatric kidney transplant recipients. Pediatr Nephrol 2019;34:2557-62. [PMID: 31520127 DOI: 10.1007/s00467-019-04346-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
76 Delion A, Girerd S, Duarte K, Girerd N, Schikowski J, Kessler M, Frimat L, Aarnink A. Which is the best predictor of de novo donor-specific antibodies in a cohort of non-sensitized first kidney transplantation: Antigenic, allelic, epitope, or physiochemical HLA mismatches? Clin Transplant 2019;33:e13508. [PMID: 30821002 DOI: 10.1111/ctr.13508] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
77 Kahl KG, Eckermann G, Frieling H, Hillemacher T. Psychopharmacology in transplantation medicine. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2019;88:74-85. [DOI: 10.1016/j.pnpbp.2018.07.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
78 Yin S, Wang X, Huang Z, Fan Y, Song T, Lin T. Tacrolimus variability score outperforms coefficient of variation in predicting clinical outcomes of living kidney transplantation. Br J Clin Pharmacol 2021. [PMID: 33899267 DOI: 10.1111/bcp.14876] [Reference Citation Analysis]
79 Mendoza Rojas A, Hesselink DA, van Besouw NM, Baan CC, van Gelder T. Impact of low tacrolimus exposure and high tacrolimus intra-patient variability on the development of de novo anti-HLA donor-specific antibodies in kidney transplant recipients. Expert Rev Clin Immunol 2019;15:1323-31. [PMID: 31721605 DOI: 10.1080/1744666X.2020.1693263] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
80 Neuberger JM, Bechstein WO, Kuypers DR, Burra P, Citterio F, De Geest S, Duvoux C, Jardine AG, Kamar N, Krämer BK, Metselaar HJ, Nevens F, Pirenne J, Rodríguez-Perálvarez ML, Samuel D, Schneeberger S, Serón D, Trunečka P, Tisone G, van Gelder T. Practical Recommendations for Long-term Management of Modifiable Risks in Kidney and Liver Transplant Recipients: A Guidance Report and Clinical Checklist by the Consensus on Managing Modifiable Risk in Transplantation (COMMIT) Group. Transplantation 2017;101:S1-S56. [PMID: 28328734 DOI: 10.1097/TP.0000000000001651] [Cited by in Crossref: 114] [Cited by in F6Publishing: 43] [Article Influence: 22.8] [Reference Citation Analysis]
81 Stefanović N, Veličković-Radovanović R, Danković K, Pavlović I, Catić-Đorđević A, Bašić J, Despotović M, Jevtović-Stoimenov T, Mitić B, Cvetković T. Effect of the Interrelation between CYP3A5 Genotype, Concentration/Dose Ratio and Intrapatient Variability of Tacrolimus on Kidney Graft Function: Monte Carlo Simulation Approach. Pharmaceutics 2021;13:1970. [PMID: 34834385 DOI: 10.3390/pharmaceutics13111970] [Reference Citation Analysis]
82 Oberbauer R, Bestard O, Furian L, Maggiore U, Pascual J, Rostaing L, Budde K. Optimization of tacrolimus in kidney transplantation: New pharmacokinetic perspectives. Transplant Rev (Orlando) 2020;34:100531. [PMID: 31955920 DOI: 10.1016/j.trre.2020.100531] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
83 Piotti G, Cremaschi E, Maggiore U. Once-daily prolonged-release tacrolimus formulations for kidney transplantation: what the nephrologist needs to know. J Nephrol 2017;30:53-61. [DOI: 10.1007/s40620-016-0316-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
84 Taber DJ, Su Z, Fleming JN, McGillicuddy JW, Posadas-Salas MA, Treiber FA, Dubay D, Srinivas TR, Mauldin PD, Moran WP. Tacrolimus Trough Concentration Variability and Disparities in African American Kidney Transplantation. Transplantation. 2017;101:2931-2938. [PMID: 28658199 DOI: 10.1097/tp.0000000000001840] [Cited by in Crossref: 39] [Cited by in F6Publishing: 19] [Article Influence: 7.8] [Reference Citation Analysis]
85 Huang C, Shu K, Ho H, Wu M. Higher Variability of Tacrolimus Trough Level Increases Risk of Acute Rejection in Kidney Transplant Recipients. Transplantation Proceedings 2016;48:1978-80. [DOI: 10.1016/j.transproceed.2016.02.081] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
86 In 't Veld AE, Grievink HW, Saghari M, Stuurman FE, de Kam ML, de Vries APJ, de Winter BCM, Burggraaf J, Cohen AF, Moerland M. Immunomonitoring of Tacrolimus in Healthy Volunteers: The First Step from PK- to PD-Based Therapeutic Drug Monitoring? Int J Mol Sci 2019;20:E4710. [PMID: 31547590 DOI: 10.3390/ijms20194710] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
87 Rodríguez-Perálvarez M, Guerrero M, De Luca L, Gros B, Thorburn D, Patch D, Aumente MD, Westbrook R, Fernández R, Amado V, Aguilar P, Montero JL, O'Beirne J, Briceño J, Tsochatzis E, De la Mata M. Area Under Trough Concentrations of Tacrolimus as a Predictor of Progressive Renal Impairment After Liver Transplantation. Transplantation 2019;103:2539-48. [PMID: 31107827 DOI: 10.1097/TP.0000000000002760] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
88 Saint-Marcoux F, Woillard JB, Monchaud C, Friedl J, Bocquentin F, Essig M, Marquet P. How to handle missed or delayed doses of tacrolimus in renal transplant recipients? A pharmacokinetic investigation. Pharmacol Res 2015;100:281-7. [PMID: 26316426 DOI: 10.1016/j.phrs.2015.08.020] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
89 Ji E, Kim MG, Oh JM. CYP3A5 genotype-based model to predict tacrolimus dosage in the early postoperative period after living donor liver transplantation. Ther Clin Risk Manag 2018;14:2119-26. [PMID: 30498355 DOI: 10.2147/TCRM.S184376] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
90 Si S, Wang Z, Yang H, Han Z, Tao J, Chen H, Wang K, Guo M, Tan R, Wei JF, Gu M. Impact of single nucleotide polymorphisms on P450 oxidoreductase and peroxisome proliferator-activated receptor alpha on tacrolimus pharmacokinetics in renal transplant recipients. Pharmacogenomics J 2019;19:42-52. [PMID: 30323313 DOI: 10.1038/s41397-018-0061-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
91 Chu MC, Smith PJ, Reynolds JM, Palmer SM, Snyder LD, Gray AL, Blumenthal JA. Depression, Immunosuppressant Levels, and Clinical Outcomes in Postlung Transplant Recipients. Int J Psychiatry Med 2020;55:421-36. [DOI: 10.1177/0091217420906637] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
92 Leino AD, King EC, Jiang W, Vinks AA, Klawitter J, Christians U, Woodle ES, Alloway RR, Rohan JM. Assessment of tacrolimus intrapatient variability in stable adherent transplant recipients: Establishing baseline values. Am J Transplant 2019;19:1410-20. [DOI: 10.1111/ajt.15199] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 9.3] [Reference Citation Analysis]
93 Ryan JL, Dandridge LM, Fischer RT. Adherence to laboratory testing in pediatric liver transplant recipients. Pediatr Transplant 2021;25:e13899. [PMID: 33131187 DOI: 10.1111/petr.13899] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
94 Larpparisuth N, Pongnatcha T, Panprom P, Promraj R, Premasathian N, Vongwiwatana A. High Intrapatient Variability in Tacrolimus Exposure Calculated Over a Long Period Is Associated With De Novo Donor-Specific Antibody Development and/or Late Rejection in Thai Kidney Transplant Patients Receiving Concomitant CYP3A4/5 Inhibitors. Ther Drug Monit 2021;43:624-9. [PMID: 33278239 DOI: 10.1097/FTD.0000000000000850] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
95 Shuker N, Shuker L, van Rosmalen J, Roodnat JI, Borra LC, Weimar W, Hesselink DA, van Gelder T. A high intrapatient variability in tacrolimus exposure is associated with poor long-term outcome of kidney transplantation. Transpl Int 2016;29:1158-67. [PMID: 27188932 DOI: 10.1111/tri.12798] [Cited by in Crossref: 67] [Cited by in F6Publishing: 58] [Article Influence: 11.2] [Reference Citation Analysis]
96 Thölking G, Filensky B, Jehn U, Schütte-Nütgen K, Koch R, Kurschat C, Pavenstädt H, Suwelack B, Reuter S, Kuypers D. Increased renal function decline in fast metabolizers using extended-release tacrolimus after kidney transplantation. Sci Rep 2021;11:15606. [PMID: 34341448 DOI: 10.1038/s41598-021-95201-5] [Reference Citation Analysis]
97 Giza P, Ficek R, Dwulit T, Chudek J, Woźniak I, Więcek A, Kolonko A. Number of Regularly Prescribed Drugs and Intrapatient Tacrolimus Trough Levels Variability in Stable Kidney Transplant Recipients. J Clin Med 2020;9:E1926. [PMID: 32575525 DOI: 10.3390/jcm9061926] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
98 Kannegieter NM, Hesselink DA, Dieterich M, de Graav GN, Kraaijeveld R, Baan CC. Differential T Cell Signaling Pathway Activation by Tacrolimus and Belatacept after Kidney Transplantation: Post Hoc Analysis of a Randomised-Controlled Trial. Sci Rep 2017;7:15135. [PMID: 29123208 DOI: 10.1038/s41598-017-15542-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
99 Flothow DJG, Suwelack B, Pavenstädt H, Schütte-Nütgen K, Reuter S. The Effect of Proton Pump Inhibitor Use on Renal Function in Kidney Transplanted Patients. J Clin Med 2020;9:E258. [PMID: 31963650 DOI: 10.3390/jcm9010258] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
100 Mo H, Kim SY, Min S, Han A, Ahn S, Min SK, Lee H, Ahn C, Kim Y, Ha J. Association of Intrapatient Variability of Tacrolimus Concentration With Early Deterioration of Chronic Histologic Lesions in Kidney Transplantation. Transplant Direct 2019;5:e455. [PMID: 31321291 DOI: 10.1097/TXD.0000000000000899] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
101 Shen CL, Wu BS, Lien TJ, Yang AH, Yang CY. BK Polyomavirus Nephropathy in Kidney Transplantation: Balancing Rejection and Infection. Viruses 2021;13:487. [PMID: 33809472 DOI: 10.3390/v13030487] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
102 Kuypers DRJ. Tacrolimus Formulations and African American Kidney Transplant Recipients: When Do Details Matter? Am J Kidney Dis 2018;71:302-5. [PMID: 29477174 DOI: 10.1053/j.ajkd.2017.10.020] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
103 Valero R, Sanchez-Fructuoso A, Rodrigo E, Belmar L, Cos MA, Perez-Flores I, Delgado J, San Millan JCR. Variability of the Mammalian Target of Rapamycin Inhibitors Is Correlated With Long-Term Renal Graft Survival. Transplant Proc 2019;51:341-3. [PMID: 30879537 DOI: 10.1016/j.transproceed.2018.08.016] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
104 Kuma Y, Ito T, Nagae K, Mizote Y, Nakahara T, Uchi H, Yamada Y, Okura M, Oda Y, Yamashita T, Furue M. Two Cases of Cutaneous Squamous Cell Carcinoma Arising in Immunosuppressed Patients with Chronic Human Papillomavirus Infection. Case Rep Dermatol 2015;7:178-82. [PMID: 26351427 DOI: 10.1159/000438504] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]